80 results
Page 2 of 4
8-K
EX-99.1
exdr5z 9eppukh7paa
8 Nov 22
Vaxart Provides Business Update and Reports Third Quarter 2022 Financial Results
4:10pm
8-K
EX-99.1
gq6det1 90h
1 Sep 22
Regulation FD Disclosure
7:05am
8-K
EX-99.2
4yjolm
1 Sep 22
Regulation FD Disclosure
7:05am
8-K
EX-99.1
zvfxdvu1h9
25 Aug 22
Vaxart Announces Highly Regarded Biotech Executive Elaine J. Heron, Ph.D. Joins Board of Directors
4:09pm
8-K
EX-99.1
wqj lsy2uvzj4
8 Aug 22
Vaxart Provides Business Update and Reports Second Quarter 2022 Financial Results
4:06pm
8-K/A
EX-99.1
uzxyh
5 Aug 22
Vaxart Stockholders Approve Proxy Proposals 2, 3 and 4
8:02am
DEFA14A
qqnjvmgz qw8qry
1 Jul 22
Additional proxy soliciting materials
5:28pm
DEFA14A
9vwcrdr
1 Jul 22
Additional proxy soliciting materials
12:32pm
8-K
EX-99.1
lrxc8 ll4ds
16 Jun 22
Management to discuss progress on its programs, annual stockholders’ meeting proposals
4:06pm
8-K
EX-99.1
m2kyxb6og14
8 Jun 22
Vaxart Announces Adjournment of Annual Meeting of Stockholders
4:06pm
8-K
EX-99.1
ocfod3w1n bv4q4yieng
9 May 22
Vaxart Provides Business Update and Reports First Quarter 2022 Financial Results
5:51pm
8-K
EX-99.1
m15jo3398uphy
24 Feb 22
Vaxart Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
4:14pm
8-K
EX-99.1
h6su02sx
15 Feb 22
Vaxart Appoints Edward Berg as Senior Vice President and General Counsel
4:02pm
8-K
EX-99.1
ijis5964qcy7
1 Dec 21
Vaxart Announces Acquisition of Second GMP Manufacturing Facility
4:00pm
8-K
EX-99.1
p89dy
4 Nov 21
Vaxart Provides Business Update and Reports Third Quarter 2021 Financial Results
4:06pm
8-K
EX-10.1
5ulr8r968lp1mrucn7u
21 Sep 21
Entry into a Material Definitive Agreement
4:18pm
8-K
EX-10.2
ep99i
21 Sep 21
Entry into a Material Definitive Agreement
4:18pm